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Abstract 
A recent study by Wang et al. [1] claims the low-frequency variant NR1H3 p.Arg415Gln is 
sufficient to cause multiple sclerosis in certain individuals and determines a patient’s likelihood of 
primary progressive disease. We sought to replicate this finding in the International MS Genetics 
Consortium (IMSGC) patient collection, which is 13-fold larger than the collection of Wang et al. 
[1], but we find no evidence that this variant is associated either with MS or disease subtype. 
Wang et al. [1] also report a common variant association in the region, which we show captures 
the association the IMSGC reported in 2013. Therefore, we conclude that the reported low-
frequency association is a false positive, likely generated by insufficient sample size. The claim 
of NR1H3 mutations describing a Mendelian form of MS - of which no examples exist - can 
therefore not be substantiated by data. 
 
 
  
Introduction 
In a recent study, Wang et al. claim an association to multiple sclerosis risk on chromosome 
11p11.2 in the locus encoding NR1H3 [1,2]. They sequenced the exomes of two affected 
individuals from a multiplex family (designated MS1) and selected 37 low-frequency missense 
variants found in both individuals for further study. After genotyping these variants in the nine 
members of that pedigree – including the initial two cases – and 185 controls, they excluded 33/37 
variants and then genotyped the remaining four variants in 2,053 MS patients and 799 healthy 
controls. They detected one variant, rs61731956 (NR1H3 p.Arg415Gln; GenBank: NM_005693.3; 
c.1244G>A), in a single additional case from another multiplex family (MS2), and from segregation 
analysis inferred that another four MS2 individuals were carriers, though only one of these has 
MS. Based on these four heterozygous cases, they claim linkage with a LOD score of 2.2, though 
the commonly accepted standard for significance is  LOD > 3.0 [3]. 
 
Results and Discussion 
We sought to validate the association of rs61731956 with MS susceptibility in our ongoing study 
of low-frequency missense variation in MS. After stringent quality control, we used linear mixed 
models to meta-analyze 32,852 cases and 36,538 controls of European ancestry in 14 country-
level strata, genotyped for 250,000 low-frequency non-synonymous variants across all exons 
using Illumina’s HumanCore Exome array. We detected the minor allele rs61731956-A in nine of 
our strata, but find no evidence of association with overall MS risk (meta-analysis β = 0.06, p = 
0.32; Table 1). As Wang et al. [1] report this association specifically with primary progressive MS 
(PPMS), we compared 1,399 PPMS cases to 13,537 relapsing remitting MS (RRMS) cases 
directly in six strata with available clinical course information, and also find no evidence of 
association with disease subtype (meta-analysis β = 2.35, p = 0.39; Table 2). Our previous linkage 
analysis of >700 multiplex families [4] further supports this conclusion (multipoint LOD = 0.0), as 
does earlier work from the Canadian Collaborative Project on the Genetic Susceptibility to Multiple 
Sclerosis (CCPGSMS) with no evidence of linkage in 40 Canadian families with four or more 
affected individuals, authored by members of the Wang et al. [1] study team [5]. 
 
Based on their interpretation of segregation patterns for rs61731956, Wang et al. [1] go on to 
genotype common variants in the NR1H3 locus in 2,053 MS patients and 799 healthy controls, 
but fail to detect any association with overall MS risk. They then report that four of their familial 
cases have a clinical course consistent with that of PPMS, and perform a secondary, stratified 
analysis of clinical course with the five tagging SNPs. They reduce their sample size to 420 PPMS 
and 1,287 RRMS patients for whom clinical course information was available, and describe an 
association between rs2279238 (OR = 1.35, p = 0.001) and PPMS, but not RRMS, risk. The 
IMSGC has already reported a disease risk association in this region [6] based on 14,498 MS 
cases and 24,091 controls to rs7120737, which is 420kb away and in moderate LD with 
rs2279238 (r2 = 0.62, D’ = 0.82 between the two variants in the 1000 Genomes CEU panel; 
IMSGC OR = 1.10, p = 1 x 10-9 for rs7120737-G). We also genotyped rs3824866, a perfect proxy 
for rs2279238 (r2 = 1, D’ = 1 in the 1000 Genomes CEU panel), which shows modest association 
to MS risk (p = 2.1 x 10-5). Conditioning on rs7120737 fully explains this association, indicating 
that the result reported by Wang et al. [1] is a modest proxy for the strong signal we have 
previously reported. 
 
Our 13-fold larger dataset therefore supports a more conventional interpretation of the data 
presented by Wang et al. [1]: there is no association between the low frequency NR1H3 
p.Arg415Gln variant rs61731956 and MS risk, but a common haplotype spanning the NR1H3 
locus is associated with overall MS susceptibility, despite the failure of Wang et al. [1] to detect it 
in their modestly sized cohort. Our data does not support an association specific to clinical course 
or PPMS. The false positive likely arose because Wang et al. [1] base their conclusions on a total 
of four affected carriers of the variant, and contravene standard practice by analyzing only five 
polymorphisms in the NR1H3 locus, not controlling for population stratification, and failing to meet 
rigorous thresholds of significance for common variation (p < 5 x 10-8) or for family-based linkage 
(LOD > 3) [3,7]. 
 
Beyond these technical issues, Wang et al. [1] appear to have succumbed to an error in logic in 
their analysis. Although individually rare, coding variants are exceedingly common in the 
population: of 7,404,909 variants identified by the Exome Aggregation Consortium (ExAC) in 
60,706 individuals, 99% have a minor allele frequency of <1% and 54% are seen exactly once in 
those data [8]. Therefore, there is complete certainty of observing at least one such variant in two 
closely related individuals, as Wang et al. [1] have done. This is reinforced by their observation of 
rs61731956-A in multiple unaffected individuals and the presence of this variant in 21/60,706 
unselected ExAC individuals. This is not a unique false positive finding, as previous studies of 
equivalently small sample size have reported MS risk associations to low-frequency coding 
variants in CYP27B1 [9] and SAIE [10], with both results failing to replicate in much larger studies 
with adequate statistical power [11-13]. 
 
We note that the experimental demonstration that p.Arg415Gln alters the heterodimerization 
efficiency between the NR1H3 product liver X receptor alpha and the retinoid X receptor alpha 
has no bearing on the association to MS pathogenesis. Many non-synonymous variants have 
dramatic effects on protein function, but in the absence of robust association to disease this alone 
cannot support a pathogenic argument [14]. 
 
The combination of our negative results from a 13-fold larger dataset and the methodological and 
logical flaws in the work presented by Wang et al. [1] categorically refute the bold claim that 
NR1H3 variation defines a Mendelian subtype of MS, which would be the first monogenic form of 
the disease ever described. Such a discovery would have enormous implications for diagnosis of 
a subset of cases, prognosis and genetic counselling of extended family members, and eventually 
for clinical management of the disease in carriers. Unfortunately, the evidence provided by Wang 
et al. [1] does not support this conclusion. 
 
 
 
 
  
  
Table 1: NR1H3 p.Arg415Gln is not associated to multiple sclerosis risk. We meta-analyzed 
32,852 cases and 36,538 controls of European ancestry in 14 country-level strata using linear 
mixed models to control for stratification. We detected the minor allele rs61731956-A in nine of 
our strata, but find no evidence of association to overall MS risk.  
 
 
 
 
 
Table 2: NR1H3 p.Arg415Gln is not associated to MS clinical course. We compared 1,399 
PPMS cases and 13,537 RRMS cases directly in six strata with available clinical course 
information, and also find no evidence of association between rs61731956-A and clinical subtype.  
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